These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24105670)

  • 21. MET: a promising anticancer therapeutic target.
    Peters S; Adjei AA
    Nat Rev Clin Oncol; 2012 May; 9(6):314-26. PubMed ID: 22566105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Salgia R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
    Lau PC; Chan AT
    Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thirty years of research on met receptor to move a biomarker from bench to bedside.
    Furlan A; Kherrouche Z; Montagne R; Copin MC; Tulasne D
    Cancer Res; 2014 Dec; 74(23):6737-44. PubMed ID: 25411347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Showering c-MET-dependent cancers with drugs.
    Knudsen BS; Vande Woude G
    Curr Opin Genet Dev; 2008 Feb; 18(1):87-96. PubMed ID: 18406132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
    Zaanan A; Laurent-Puig P; Taieb J
    Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
    Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
    Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
    Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
    Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.
    Jiang WG; Martin TA; Parr C; Davies G; Matsumoto K; Nakamura T
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):35-69. PubMed ID: 15607934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
    Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the HGF/Met signalling pathway in cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
    Hack SP; Bruey JM; Koeppen H
    Oncotarget; 2014 May; 5(10):2866-80. PubMed ID: 24930887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors.
    Haddad R; Lipson KE; Webb CP
    Anticancer Res; 2001; 21(6B):4243-52. PubMed ID: 11908677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
    Toschi L; Jänne PA
    Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.
    Gao J; Inagaki Y; Song P; Qu X; Kokudo N; Tang W
    Pharmacol Res; 2012 Jan; 65(1):23-30. PubMed ID: 22138044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET receptor in oncology: From biomarker to therapeutic target.
    Malik R; Mambetsariev I; Fricke J; Chawla N; Nam A; Pharaon R; Salgia R
    Adv Cancer Res; 2020; 147():259-301. PubMed ID: 32593403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.